Last reviewed · How we verify
NCT03434548
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
trial testing PET imaging in Huntington Disease in 113 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | King's College London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 113 |
| Start date | 20 July 2021 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PET imaging
- Multi-modal MRI imaging
Conditions studied
- Huntington Disease — all drugs for Huntington Disease →
Sponsor
King's College London
Who can join
Adults 21 to 75, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over a three (3) year period (Baseline, Year-1, and Year-2).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03434548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET imaging
Trials testing the same drug.
- NCT06586047 — Breast Cancer PSMA PET · EARLY_PHASE1 · recruiting
- NCT05753995 — Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study · NA · active not recruiting
- NCT05634031 — Imaging Coronary Microvascular Dysfunction (CMD) Study · NA · recruiting
- NCT04073810 — Residual Inflammation and Plaque Progression Long-term Evaluation · active not recruiting
- NCT03298009 — Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF) · NA · withdrawn
Other recruiting trials for Huntington Disease
Currently open trials in the same condition.
- NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
- NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
- NCT06774443 — Hinting Task for Huntington's Disease · recruiting
- NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
- NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting
Other King's College London trials
Trials by the same sponsor.
- NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
- NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
- NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03434548 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College London
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03434548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing